Ma X, Ling Y, Li P, Sun P, Cao Y, Bai X
J Virol. 2020; 94(16).
PMID: 32493819
PMC: 7394891.
DOI: 10.1128/JVI.00273-20.
Gao Y, Sun S, Guo H
Virol J. 2016; 13:107.
PMID: 27334704
PMC: 4917953.
DOI: 10.1186/s12985-016-0561-z.
Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D
J Virol. 2014; 88(8):4008-20.
PMID: 24453363
PMC: 3993757.
DOI: 10.1128/JVI.03594-13.
Gladue D, ODonnell V, Baker-Branstetter R, Holinka L, Pacheco J, Fernandez Sainz I
J Virol. 2013; 87(12):6794-803.
PMID: 23576498
PMC: 3676138.
DOI: 10.1128/JVI.00448-13.
Gladue D, ODonnell V, Baker-Branstetter R, Holinka L, Pacheco J, Fernandez-Sainz I
J Virol. 2012; 86(22):12080-90.
PMID: 22933281
PMC: 3486479.
DOI: 10.1128/JVI.01610-12.
Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells.
Marissen W, Lloyd R
Mol Cell Biol. 1998; 18(12):7565-74.
PMID: 9819442
PMC: 109337.
DOI: 10.1128/MCB.18.12.7565.
Intracellular membrane proliferation in E. coli induced by foot-and-mouth disease virus 3A gene products.
Weber S, Granzow H, Weiland F, Marquardt O
Virus Genes. 1996; 12(1):5-14.
PMID: 8879115
DOI: 10.1007/BF00369995.
Biologically active protease of foot and mouth disease virus is expressed from cloned viral cDNA in Escherichia coli.
Klump W, Marquardt O, Hofschneider P
Proc Natl Acad Sci U S A. 1984; 81(11):3351-5.
PMID: 6328511
PMC: 345505.
DOI: 10.1073/pnas.81.11.3351.
Biochemical map of polypeptides specified by foot-and-mouth disease virus.
Grubman M, Robertson B, MORGAN D, Moore D, Dowbenko D
J Virol. 1984; 50(2):579-86.
PMID: 6323757
PMC: 255676.
DOI: 10.1128/JVI.50.2.579-586.1984.
In vitro morphogenesis of foot-and-mouth disease virus.
Grubman M
J Virol. 1984; 49(3):760-5.
PMID: 6321761
PMC: 255535.
DOI: 10.1128/JVI.49.3.760-765.1984.
Implications of the picornavirus capsid structure for polyprotein processing.
Arnold E, Luo M, Vriend G, Rossmann M, Palmenberg A, Parks G
Proc Natl Acad Sci U S A. 1987; 84(1):21-5.
PMID: 3467351
PMC: 304133.
DOI: 10.1073/pnas.84.1.21.
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts.
Vakharia V, Devaney M, Moore D, Dunn J, Grubman M
J Virol. 1987; 61(10):3199-207.
PMID: 3041041
PMC: 255898.
DOI: 10.1128/JVI.61.10.3199-3207.1987.
Genomic structure of the large RNA segment of infectious bursal disease virus.
Hudson P, McKern N, Power B, Azad A
Nucleic Acids Res. 1986; 14(12):5001-12.
PMID: 3014441
PMC: 311506.
DOI: 10.1093/nar/14.12.5001.
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins.
Strebel K, Beck E, Strohmaier K, Schaller H
J Virol. 1986; 57(3):983-91.
PMID: 3005640
PMC: 252830.
DOI: 10.1128/JVI.57.3.983-991.1986.
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12.
Robertson B, Grubman M, Weddell G, Moore D, Welsh J, Fischer T
J Virol. 1985; 54(3):651-60.
PMID: 2987518
PMC: 254848.
DOI: 10.1128/JVI.54.3.651-660.1985.
Purification and partial characterization of poliovirus protease 2A by means of a functional assay.
Konig H, Rosenwirth B
J Virol. 1988; 62(4):1243-50.
PMID: 2831385
PMC: 253133.
DOI: 10.1128/JVI.62.4.1243-1250.1988.
An apparent deletion of an oligonucleotide detected by RNA fingerprint in the nondiabetogenic B variant of encephalomyocarditis virus is caused by a point mutation.
Yoon J, Wong A, Bae Y, Eun H
J Virol. 1988; 62(2):637-40.
PMID: 2826821
PMC: 250583.
DOI: 10.1128/JVI.62.2.637-640.1988.
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
Baxt B, Vakharia V, Moore D, Franke A, MORGAN D
J Virol. 1989; 63(5):2143-51.
PMID: 2467993
PMC: 250631.
DOI: 10.1128/JVI.63.5.2143-2151.1989.
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells.
Grubman M, MORGAN D, Kendall J, Baxt B
J Virol. 1985; 56(1):120-6.
PMID: 2411948
PMC: 252492.
DOI: 10.1128/JVI.56.1.120-126.1985.
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
Saiz J, Gonzalez M, Borca M, Sobrino F, Moore D
J Virol. 1991; 65(5):2518-24.
PMID: 1707983
PMC: 240607.
DOI: 10.1128/JVI.65.5.2518-2524.1991.
